-+ 0.00%
-+ 0.00%
-+ 0.00%

Avalo Therapeutics Q3 EPS $(2.19) Misses $(1.61) Estimate

Benzinga·11/06/2025 12:16:38
Listen to the news
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(2.19) per share which missed the analyst consensus estimate of $(1.61) by 35.6 percent. This is a 22.61 percent increase over losses of $(2.83) per share from the same period last year.